Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report

Abstract Background Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative in a variety of hematological malignancies. Graft-vs.-host disease (GvHD) remains a life-threatening complication. Standard treatment is high-dose (HD) corticosteroids. Steroid-refractory (SR) GvHD...

Full description

Bibliographic Details
Main Authors: Enrico Maffini, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Ilaria Buondonno, Dario Ferrero, Mario Boccadoro, Chiara Dellacasa, Alessandro Busca, Domenico Novero, Benedetto Bruno
Format: Article
Language:English
Published: BMC 2016-08-01
Series:Journal of Hematology & Oncology
Subjects:
Allogeneic hematopoietic stem cell transplant (HSCT)
Steroid-refractory graft-vs.-host disease (SR-GvHD)
Ruxolitinib
Regulatory T cells (Treg)
Proinflammatory cytokines
Case report
Online Access:http://link.springer.com/article/10.1186/s13045-016-0298-6

Internet

http://link.springer.com/article/10.1186/s13045-016-0298-6

Similar Items